Global /United States /Healthcare /Drug Manufacturers - Specialty & Generic /PRPH
chevron_leftBack
P

ProPhase Labs, Inc.

PRPH
OTCMKTS: PRPH Delayed
0.1300USD -7.1%
As of 14 June 2026, ProPhase Labs, Inc. has a market cap of $1.24M USD, ranking #48149 globally and #6166 in the United States. It ranks #4271 in the Healthcare sector, and #341 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
48149
Country Rank
6166
Sector Rank
4271
Industry Rank
341
Key Stats
Market Cap
$1.24MUSD
Enterprise Value
$9.77MUSD
Revenue (TTM)
$4.9MUSD
EBITDA (TTM)
-$11.91MUSD
Net Income (TTM)
-$13.35MUSD
EBITDA Margin
-243%
Profit Margin
-272%
PS Ratio
0.3
PB Ratio
0.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ted Karkus open_in_new
Employees
96
Founded
1989
Website
prophaselabs.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-7.1% 37% 76% -40% -97% -96%

News

Loading...

Markets

Exchange Ticker Price
OTC Markets
MIC: OTCM
PRIMARY
PRPH
ISIN: US74345W2070
Shares Out.:
9.493M1 Shares Float: 9.161M2
TV:
SA:
YF:
GF:
BA:
MS:
0.1300 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About ProPhase Labs, Inc.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer’s disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (United States)
Name
Market Cap diff.
PE
$29.56B
2M%
-
INDV
$2.07B
1.54B GBP
167K%
-
NDOI
$1.8B
145K%
0.4
$1.76B
142K%
-
$1.33B
107K%
-
$1.02B
83K%
12.1
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$36.75B
108.92B ILS
3M%
24.2
$15.84B
107.34B CNY
1M%
16.0
CIPLA
$11.16B
1.06T INR
902K%
23.4
LUPIN
$11.04B
1.05T INR
893K%
22.7
$9.09B
61.6B CNY
735K%
80.6
$8.74B
7.57B EUR
707K%
-
chevron_leftBack